Ascend Expands Antimicrobial Acteev™ Technology Into Finished Goods Line to Combat COVID-19 Spread
10.9.2020 17:53:00 EEST | Business Wire | Press release
A new line of face masks combining comfort with protection is available from Acteev™ by Ascend Performance Materials, a manufacturer of technology-forward textiles and engineered materials. The brand’s first product, the Acteev Protect™ Nonwoven Mask, is a reusable general purpose mask that features powerful built-in antimicrobial technology to protect the mask from odor-causing bacteria and mold fungi in a soft, breathable, comfortable fabric that is gentle on the skin.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200910005748/en/
The Acteev Protect Nonwoven Mask is a reusable general purpose mask that features powerful built-in antimicrobial technology to protect the mask from odor-causing bacteria and mold fungi in a soft, breathable, comfortable fabric that is gentle on the skin. (Photo: Business Wire)
The mask is the first in a series of planned Acteev product introductions that will include a knit fabric mask and a sports gaiter. The company also announced it is designing an N95 respirator and a line of surgical masks and is developing more engineering plastics solutions for high-touch surfaces such as light switches and tray tables; textiles for use in scrubs and hospital gowns; and nonwoven fibers and rolled goods for use in applications such as filtration systems.
The expansion into masks is a natural extension for Ascend, which is the largest producer of nylon 6,6 resin in the world, said Lu Zhang, Ph.D., who joined Ascend earlier this year as vice president and leader of the Acteev business. “The nylon Ascend makes is durable enough to be used under the hood of a car, but when it’s spun into fibers, it can be woven or knitted into fabrics that are soft and silky,” she said. “Combined with our antimicrobial Acteev technology, our fabric makes an Acteev Protect Nonwoven Mask more breathable, more comfortable and more wearable than anything else we’ve encountered in the market.”
The Acteev Protect Nonwoven Mask is an ideal choice for anyone seeking better protection, comfort and breathability than a typical blue mask and better availability than an N95 respirator, which are reserved for health care workers, Zhang said.
“Masks only inhibit the spread if they’re worn – that’s why comfort and breathability are so important,” Zhang said. “As we send our kids back to school, return to the workplace, resume shopping and otherwise get back to normal life, we need an option that is long-lasting and wearable for hours.
“They’re great for teachers, restaurant staff, transportation workers, industrial personnel and anyone whose lifestyle takes them out of their homes and into the world,” Zhang said.
Darayus Pardivala, the president of the Americas division of Sulzer Rotating Equipment Services, purchased the masks for employees at all 32 of the company’s locations in North and South America. “They’re much easier to breathe through compared to what we had in the past, there’s an added level of protection and our employees are much more comfortable,” Pardivala said. “The pushback we had in the past about wearing masks is completely gone.”
Recent testing on the knit fabric completed at the University of Cambridge has demonstrated that Acteev technology deactivates the virus that causes COVID-19, SARS-CoV-2, with 99.9% efficacy on contact1. Ascend is working with the U.S. Environmental Protection Agency, the U.S. Food and Drug Administration and other governmental agencies to obtain the appropriate regulatory clearances to make specific claims regarding the technology’s antiviral properties.
Acteev Protect Nonwoven Masks are made with Acteev™ technology with active zinc ions in a polymer matrix to destroy microbes.
“Acteev’s active layer of defense uses safe, environmentally friendly active zinc ions embedded into the matrix of the polymer – not a chemical spray that will wash away or flake off – meaning these masks can be used again and again,” said Phil McDivitt, CEO of Ascend.
The Acteev Protect Nonwoven Masks are constructed with three layers of zinc-embedded materials.
“Our scientists and engineers invented a process for creating a revolutionary new fabric that checks all the boxes,” McDivitt said. “Acteev™ fabric is soft to the touch and moisture-wicking to keep the face cool, and it’s more breathable than other materials used in masks.”
Product availability can be found at acteev.com and on social media: @acteevbyascend on Instagram, Twitter and Facebook.
About Ascend Performance Materials
Ascend Performance Materials makes high-performance materials for everyday essentials and new technologies. Our focus is on improving quality of life and inspiring a better tomorrow through innovation. Based in Houston, Texas, and with regional offices in Shanghai, Brussels and Detroit, we are a fully integrated material solutions provider with eight global manufacturing facilities in the United States, Europe and China. Our 2,600-person global workforce makes the plastics, fabrics, fibers and chemicals used to make safer vehicles, cleaner energy, better medical devices, smarter appliances and longer-lasting apparel and consumer goods. We are committed to safety, sustainability and the success of our customers and our communities.
Find out more about Ascend at www.ascendmaterials.com.
About Acteev: acteev.com
- Tests show >99% antiviral, antibacterial, antifungal efficacy1
- EPA-registered zinc ions embedded in the polymer
- Hygroscopic nylon 6,6 fabric attracts moisture, which activates the zinc ions
- Not a topical treatment or coating
- Not dependent on silver, copper
-
Proven efficacy in many end forms:
- Knit and woven fabrics for consumer textiles, upholstery, uniforms, face masks
- Nanofiber, meltblown and spunbond nonwovens for filtration
- Fibers for carpets
- Engineered plastics for high-touch surfaces
1DISCLAIMER: Acteev™ technology has been shown in laboratory tests to destroy SARS-CoV-2, the coronavirus that causes COVID-19, and other pathogens including H1N1, coronavirus 229E and Gram-positive and Gram-negative bacteria such as staphylococcus and E. coli. All data presented on this page comes from testing performed by independent third-party laboratories. Testing conducted on various end forms. Testing by University of Cambridge found a >3 log (99.9%) reduction in SARS-CoV-2 and H1N1 viruses upon instant contact on polyamide 66 textile fabric with Acteev technology as compared to an identical basis weight polyamide 66 textile fabric without Acteev technology. Acteev Protect does not protect users or others against disease-causing bacteria. Not all claims are permitted in all jurisdictions, including in the United States. Some device designs currently under review with the U.S. Food and Drug Administration. Ascend has more than 15 patent families pending on Acteev technology.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200910005748/en/
Contact information
Nicki Britton, +1 832-205-4854, nbritt@ascendmaterials.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
